

Friday, 14 May 2004

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

Dear Sir

FOR IMMEDIATE ANNOUNCEMENT

Appointment of Dr James Williams as Chief Executive Officer

The Board of Resonance Health Limited (ASX code **RHT**) is very pleased to announce the appointment of Dr James Williams to the position of Chief Executive Officer for its 51% operating subsidiary, Inner Vision Biometrics Pty Ltd (“IVB”), effective 17 May 2004.

Dr Williams’ appointment as Chief Executive Officer of IVB is a further significant step in advancing the commercialisation of the company’s FerriScan liver iron measurement test. Resonance Health Limited Managing Director, Mr Tony Fitzgerald said that the appointment of Dr Williams as full time CEO of the company would ensure that the commercialisation plan had a major driver, with strong commercial and academic qualifications to ensure the successful rollout of the FerriScan test in Australia and Europe, as initially envisaged by the group.

In April 2004, IVB lodged an application for approval of the FerriScan test with the Therapeutic Goods Administration in Australia. Receipt of TGA approval in Australia would also provide the company with CE mark approval to market the test in Europe. The company recently announced a “Commercial Collaboration” with MedTel UK Ltd, a division of the international radiology group Med-Tel International Corporation, to provide the FerriScan test service in the UK, following registration approvals.

Profile – Dr James Williams

Dr James Williams BSc (Honours) (Aberdeen), PhD (Melbourne), MBA (UWA) has broad experience in the commercialisation of medical technologies. He has been involved in projects relating to medical devices, telemedicine, tissue transplantation, drug discovery and delivery, cancer diagnostics and nano technology. He has led, as Managing

Director, the commercialisation of a technology project developing a medical device through to commercial production with key regulatory approvals (United States, Australia and Europe) and a global launch of the product.

Prior to his involvement in biotechnology commercialisation projects, Dr Williams led a University based research group investigating the molecular and cell biology of blood development and cancer.

He has attracted nationally competitive research grants, for both academic and commercial projects, and has published extensively in leading, peer reviewed, international journals. In addition, Dr Williams is named as an inventor on patent applications in the areas of gene therapy and diagnosis, drug delivery, medical devices and IT-based business processes.

Dr Williams has provided commercialisation management services to start-up and early stage companies and he is the current Chair of the Western Australian Branch of AusBiotech.

ABOUT THE COMPANY

Resonance Health Limited controls 51% of the voting rights of Inner Vision Biometrics Pty Ltd (IVB) and is earning 51% of the equity of IVB via the progressive injection of further capital. IVB is the 100% owner of **FerriScan**.

FerriScan is a novel, non-invasive liver diagnostic test with global applications. The test accurately measures the iron content of a patient's liver to assist clinicians in the detection and treatment of iron overload disorders such as Thalassemia and Hereditary Haemochromatosis. It is intended that the FerriScan test will replace the need for liver biopsy and become a valuable adjunct to gene testing for iron overload diseases. Liver biopsy is an unpleasant, invasive procedure requiring liver tissue to be extracted from the patient by needle.

For more information please contact:

Tony Fitzgerald
Managing Director
Resonance Health Limited
08 9389 5933
tfitzgerald@resonancehealth.com